

Jennifer R Brown

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8158051/jennifer-r-brown-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

290
papers

15,371
citations

56
h-index

121
g-index

307
ext. papers

18,241
ext. citations

6.4
avg, IF

6.35
L-index

#	Paper	IF	Citations
290	Activation of Notch and Myc signaling via B cell-restricted depletion of Dnmt3a generates a consistent murine model of chronic lymphocytic leukemia. <i>Cancer Research</i> , 2021 ,	10.1	1
289	Venetoclax plus Dose-Adjusted R-EPOCH (VR-EPOCH) for Richter's Syndrome. <i>Blood</i> , 2021 ,	2.2	8
288	Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021 , 138, 640-640	2.2	0
287	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021 , 138, 639-639	2.2	2
286	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021 , 138, 391-391	2.2	2
285	Novel Mechanisms of Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia By Whole Genome Methylation Sequencing. <i>Blood</i> , 2021 , 138, 4361-4361	2.2	
284	Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B cell malignancies. <i>Molecular Oncology</i> , 2021 ,	7.9	1
283	Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. <i>Lancet Haematology</i> , 2021 , 8, e912-e921	14.6	8
282	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet</i> , 2021 , 397, 892-901	40	81
281	Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target. <i>Frontiers in Immunology</i> , 2021 , 12, 662866	8.4	4
280	Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia. <i>Blood</i> , 2021 , 138, 44-56	2.2	7
279	Multi-Factor Clustering Incorporating Cell Motility Predicts T Cell Expansion Potential. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 648925	5.7	0
278	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. <i>Leukemia</i> , 2021 , 35, 3201-3211	10.7	4
277	Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course. <i>Frontiers in Oncology</i> , 2021 , 11, 640731	5.3	3
276	High-grade heart block associated with ibrutinib therapy. <i>HeartRhythm Case Reports</i> , 2021 , 7, 391-394	1	1
275	PI3K inhibitors are finally coming of age. <i>Nature Reviews Drug Discovery</i> , 2021 , 20, 741-769	64.1	45
274	Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. <i>Cancer Discovery</i> , 2021 ,	24.4	5

273	Targeting Bruton's Tyrosine Kinase in CLL. <i>Frontiers in Immunology</i> , 2021 , 12, 687458	8.4	11
272	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <i>Leukemia</i> , 2021 , 35, 3059-3072	10.7	6
271	IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K inhibitor idelalisib. <i>Haematologica</i> , 2021 , 106, 2995-2999	6.6	2
270	miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. <i>Blood</i> , 2021 , 137, 2481-2494	2.2	12
269	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. <i>Blood Cancer Discovery</i> , 2021 , 2, 54-69	7	6
268	Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. <i>Nature</i> , 2021 , 590, 157-162	50.4	18
267	A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. <i>Leukemia and Lymphoma</i> , 2021 , 62, 478-481	1.9	
266	A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. <i>Leukemia</i> , 2021 , 35, 1064-1072	10.7	12
265	AKT: a key to RT?. <i>Blood</i> , 2021 , 137, 582-584	2.2	0
264	A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. <i>Investigational New Drugs</i> , 2021 , 39, 1099-1105	4.3	2
263	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021 , 35, 2854-2861	10.7	2
262	Idelalisib immune-related toxicity is associated with improved treatment response. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2915-2920	1.9	4
261	The future of antibody therapy in chronic lymphocytic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2021 , 26, 323-336	3.7	0
260	The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2021 , 35, 807-826	3.1	1
259	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. <i>Haematologica</i> , 2021 , 106, 3219-3222	6.6	7
258	Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies. <i>Blood Advances</i> , 2021 , 5, 3062-3065	7.8	11
257	Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. <i>Lancet Oncology</i> , 2021 , 22, 1391-1402	21.7	18
256	Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. <i>American Journal of Hematology</i> , 2021 , 96, E95-E98	7.1	10

255	4321 Personalization of T cell production for cellular immunotherapy. <i>Journal of Clinical and Translational Science</i> , 2020 , 4, 15-15	0.4	
254	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020 , 4, 858-867	7.8	21
253	Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. <i>Blood</i> , 2020 , 136, 2918-2926	2.2	21
252	Inverting the BTK-BCL2 order. <i>Blood</i> , 2020 , 135, 2205-2207	2.2	1
251	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020 , 135, 1204-1213	2.2	81
250	Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. <i>Blood Advances</i> , 2020 , 4, 1458-1463	7.8	16
249	Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement. <i>Blood</i> , 2020 , 136, 29-30	2.2	
248	Genetic Determinants and Evolutionary History of Richter's Syndrome. <i>Blood</i> , 2020 , 136, 47-48	2.2	3
247	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020 , 136, 45-49	2.2	2
246	Evolving Treatment Patterns in Chronic Lymphocytic Leukemia Among Experts and Community Practitioners: Analysis of an Online Decision Support Tool. <i>Blood</i> , 2020 , 136, 41-42	2.2	
245	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 22-23	2.2	0
244	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. <i>Blood</i> , 2020 , 136, 37-38	2.2	0
243	The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL. <i>Blood</i> , 2020 , 136, 3-4	2.2	2
242	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2020 , 136, 35-37	2.2	11
241	Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome. <i>Blood</i> , 2020 , 136, 46-47	2.2	6
240	Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020 , 136, 20-21	2.2	13
239	A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter's syndrome. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8004-8004	2.2	5
238	Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202. <i>Journal of Clinical Oncology</i> , 2020 , 38, e20004-e20004	2.2	

237	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020 , 136, 1134-1143	2.2	132
236	Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib. <i>Leukemia</i> , 2020 , 34, 3404-3407	10.7	2
235	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. <i>Blood Advances</i> , 2020 , 4, 4113-4123	7.8	13
234	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020 , 4, 3977-3989	7.8	30
233	Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	7
232	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. <i>HemaSphere</i> , 2020 , 4, e432	0.3	15
231	Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. <i>Cancer Cell</i> , 2019 , 36, 369-384.e13	24.3	107
230	Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, S283	2	2
229	Cardiovascular Toxicities Associated With Ibrutinib. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1667-1678	15.1	85
228	Growth dynamics in naturally progressing chronic lymphocytic leukaemia. <i>Nature</i> , 2019 , 570, 474-479	50.4	47
227	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019 , 133, 2031-2042	20.42	123
226	For CLL cells, there's no place like home. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3347-3349	1.9	1
225	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019 , 6, e419-e428	14.6	41
224	Advances in drug-based therapies in chronic lymphocytic leukemia and future prospects. <i>Advances in Cell and Gene Therapy</i> , 2019 , 2, e51	1.2	
223	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019 , 25, 5143-5155	12.9	6
222	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019 , 94, 1353-1363	7.1	152
221	Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. <i>Mycoses</i> , 2019 , 62, 1140-1147	5.2	38
220	PI3K p110 α inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. <i>Journal of Clinical Investigation</i> , 2019 , 129, 122-136	15.9	27

219	Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). <i>Blood</i> , 2019 , 134, 762-762	2.2	41
218	Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial. <i>Blood</i> , 2019 , 134, 4312-4312	2.2	1
217	Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLL. <i>Blood</i> , 2019 , 134, 1745-1745	2.2	1
216	A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation. <i>Blood</i> , 2019 , 134, 4318-4318	2.2	7
215	High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR). <i>Blood</i> , 2019 , 134, 4291-4291	2.2	1
214	ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma. <i>Blood</i> , 2019 , 134, 5244-5244	2.2	2
213	LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL. <i>Blood</i> , 2019 , 134, 478-478	2.2	6
212	Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies. <i>Blood</i> , 2019 , 134, 1756-1756	2.2	1
211	A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL. <i>Blood</i> , 2019 , 134, 1763-1763	2.2	6
210	Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019 , 134, 32-32	2.2	25
209	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study. <i>Blood</i> , 2019 , 134, 3039-3039	2.2	1
208	Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents. <i>Blood</i> , 2019 , 134, 3321-3321	2.2	2
207	High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019 , 134, 2571-2571	2.2	
206	Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL). <i>Blood</i> , 2019 , 134, 516-516	2.2	
205	Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study. <i>Blood</i> , 2019 , 134, 3048-3048	2.2	
204	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019 , 94, 554-562	7.1	20
203	Phosphatidylinositol 3 Kinase Inhibitors: Present and Future. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 394-400	2.2	10
202	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. <i>Blood Advances</i> , 2019 , 3, 1553-1562	7.8	101

201	Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2019 , 3, 1167-1174	7.8	16
200	Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. <i>Lancet Haematology, the</i> , 2019 , 6, e38-e47	14.6	70
199	Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. <i>Blood</i> , 2019 , 133, 990-992	2.2	6
198	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1312-1315	1.9	1
197	Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. <i>British Journal of Haematology</i> , 2019 , 184, 558-569	4.5	51
196	Ibrutinib: searching for a partner drug. <i>Lancet Oncology, The</i> , 2019 , 20, 3-5	21.7	2
195	MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL. <i>British Journal of Haematology</i> , 2019 , 184, 925-936	4.5	7
194	Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. <i>Lancet Haematology, the</i> , 2018 , 5, e170-e180	14.6	28
193	Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?. <i>Expert Review of Hematology</i> , 2018 , 11, 185-194	2.8	38
192	Enhanced activation and expansion of T cells using mechanically soft elastomer fibers. <i>Advanced Biology</i> , 2018 , 2, 1700167	3.5	23
191	How I treat CLL patients with ibrutinib. <i>Blood</i> , 2018 , 131, 379-386	2.2	74
190	Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2018 , 9, 3-19	5.7	16
189	Ibrutinib: coming of age?. <i>Blood</i> , 2018 , 131, 1880-1882	2.2	3
188	Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2767-2768	1.9	1
187	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018 , 132, 145-145	2.2	4
186	Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study. <i>Blood</i> , 2018 , 132, 1856-1856	2.2	2
185	Activating MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018 , 132, 587-587	2.2	7
184	Mass Cytometry Identifies T Cell Populations Associated with Severe Hepatotoxicity in CLL Patients on Upfront Idelalisib. <i>Blood</i> , 2018 , 132, 4413-4413	2.2	1

183	Phase 3 zanubrutinib (BGB-3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS7581-TPS7581	2.2	4
182	Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. <i>PLoS ONE</i> , 2018 , 13, e0193249	3.7	5
181	Dynamic BH3 Profiling Predicts Patient Response and MRD Status in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Frontline Treatment with Kinase Inhibitor Plus FCR (KI+FCR). <i>Blood</i> , 2018 , 132, 4395-4395	2.2	
180	Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018 , 132, 820-820	2.2	
179	Idelalisib Plus Anti-CD20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL. <i>Blood</i> , 2018 , 132, 5564-5564	2.2	
178	Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1986-1989	1.9	1
177	The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars. <i>Oncologist</i> , 2018 , 23, 288-296	5.7	3
176	Relapsed CLL: sequencing, combinations, and novel agents. <i>Hematology American Society of Hematology Education Program</i> , 2018 , 2018, 248-255	3.1	7
175	Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2018 , 34, 982-995.e7	24.3	58
174	DUO delivers for duvelisib. <i>Blood</i> , 2018 , 132, 2422-2424	2.2	3
173	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018 , 379, 2517-2528	59.2	455
172	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology, The</i> , 2017 , 18, 297-311	21.7	173
171	Ventricular arrhythmias and sudden death in patients taking ibrutinib. <i>Blood</i> , 2017 , 129, 2581-2584	2.2	120
170	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. <i>Lancet Haematology, the</i> , 2017 , 4, e114-e126	14.6	149
169	Phosphatidylinositol 3-kinase blockade increases genomic instability in B cells. <i>Nature</i> , 2017 , 542, 489-493	33.4	88
168	Lenalidomide in the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 633-650	5.9	25
167	The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2287-2297	1.9	7
166	Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. <i>Drugs and Aging</i> , 2017 , 34, 509-527	4.7	27

165	PI3K selective and PI3K/PTEN combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1267-1279	5.9	44
164	Opportunistic Infections (OIs) in Patients with Hematologic Malignancies (HM) Treated with Bruton's Tyrosine Kinase (BTK) and Phosphoinositide 3 Kinase (PI3K) Inhibitors: An 8-Year Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S699-S699	1	4
163	Reply to S. Opat et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4094-4095	2.2	1
162	Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2989-2992	2.2	10
161	Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. <i>Current Oncology Reports</i> , 2017 , 19, 61	6.3	13
160	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. <i>Haematologica</i> , 2017 , 102, 1796-1805	6.6	150
159	Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. <i>Genome Research</i> , 2017 , 27, 1300-1311	9.7	50
158	Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?. <i>Expert Review of Hematology</i> , 2017 , 10, 707-718	2.8	7
157	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017 , 35, 24-31	2.2	105
156	Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. <i>Clinical Cancer Research</i> , 2017 , 23, 735-745	12.9	62
155	A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities. <i>British Journal of Haematology</i> , 2017 , 178, 820-823	4.5	4
154	Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7505-7505	2.2	11
153	Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7510-7510	2.2	11
152	Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2016 , 101, e295-8	6.6	54
151	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. <i>Lancet Oncology</i> , 2016 , 17, 1409-1418	21.7	233
150	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nature Communications</i> , 2016 , 7, 11589	17.4	220
149	Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2016 , 30, 750-763	24.3	115
148	Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016 , 172, 735-44	4.5	88

147	A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016 , 173, 89-95	4.5	44
146	Physical Examination for the Academic Psychiatrist: Primer and Common Clinical Scenarios. <i>Academic Psychiatry</i> , 2016 , 40, 321-7	1.1	4
145	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016 , 374, 323-32	59.2	621
144	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016 , 374, 311-22	59.2	1164
143	Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL. <i>MAbs</i> , 2016 , 8, 787-98	6.6	6
142	The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016 , 43, 260-4	5.5	32
141	Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL. <i>Blood</i> , 2016 , 128, 231-231	2.2	4
140	Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. <i>Blood</i> , 2016 , 128, 3243-3243	2.2	14
139	A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials. <i>Blood</i> , 2016 , 128, 3705-3705	2.2	22
138	Acalabrutinib Increases Mitochondrial Priming and Enhances Venetoclax Sensitivity in CLL Cells. <i>Blood</i> , 2016 , 128, 4346-4346	2.2	2
137	Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy. <i>Blood</i> , 2016 , 128, 621-621	2.2	16
136	TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. <i>Blood</i> , 2016 , 128, 641-641	2.2	10
135	Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7520-7520	2.2	8
134	Simultaneous inhibition of Vps34 kinase would enhance PI3K inhibitor cytotoxicity in the B-cell malignancies. <i>Oncotarget</i> , 2016 , 7, 53515-53525	3.3	14
133	Characterization of selective and potent PI3K inhibitor (PI3KDIN- 015) for B-Cell malignances. <i>Oncotarget</i> , 2016 , 7, 32641-51	3.3	7
132	Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, e387-98	7.1	17
131	FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016 , 91, 978-83	7.1	11
130	Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. <i>Blood</i> , 2016 , 128, 2899-2908	2.2	52

129	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 128, 2931-2940	2.2	75
128	Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. <i>Blood</i> , 2016 , 127, 2598-606	2.2	16
127	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. <i>Blood</i> , 2016 , 127, 3215-24	2.2	181
126	Dual TORC1/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 128, 574-83	2.2	54
125	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016 , 128, 195-203	2.2	222
124	Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. <i>Blood</i> , 2016 , 128, 1609-13	2.2	58
123	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2117-2125	4.7	70
122	Discovery of a Series of 5,11-Dihydro-6-benzo[<i>d</i>]pyrimido[5,4- <i>b</i>][1,4]diazepin-6-ones as Selective PI3K- β Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2016 , 7, 908-912	4.3	13
121	Management of adverse events associated with idelalisib treatment: expert panel opinion. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2779-86	1.9	221
120	Obinutuzumab: its use in the management of chronic lymphocytic leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 843-853	1.1	
119	The rosy future of BCL-2 inhibition in chronic lymphocytic leukemia: pursuit of a worthy target. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2755-6	1.9	
118	Phase I Trial of the Pan-PI3K Inhibitor Piliaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2015 , 21, 3160-9	12.9	46
117	The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 125, 2915-22	2.2	92
116	Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. <i>Blood</i> , 2015 , 125, 2779-85	2.2	63
115	Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. <i>British Journal of Haematology</i> , 2015 , 170, 694-703	4.5	16
114	The Clonal Architecture of CXCR4 mutations in Waldenström's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability. <i>Blood</i> , 2015 , 126, 1486-1486	2.2	1
113	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 1713-1713	2.2	1
112	Altered Expression of Functional Proteins in CD4 Regulatory T Cells during Therapy with Idelalisib. <i>Blood</i> , 2015 , 126, 1735-1735	2.2	4

111	Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 3156-3156	2.2	2
110	Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL. <i>Blood</i> , 2015 , 126, 4158-4158	2.2	9
109	A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed By Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL. <i>Blood</i> , 2015 , 126, 4159-4159	2.2	1
108	Enhancer Landscapes Reveal Transcription Factor Network Dependencies in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 436-436	2.2	3
107	Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLL. <i>Blood</i> , 2015 , 126, 490-490	2.2	15
106	Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities. <i>Blood</i> , 2015 , 126, 497-497	2.2	20
105	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 522-522	2.2	3
104	Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e18030-e18030	2.2	7
103	Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. <i>PLoS ONE</i> , 2015 , 10, e0143685	3.7	25
102	The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile. <i>Blood</i> , 2015 , 126, 831-831	2.2	
101	Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis. <i>Blood</i> , 2015 , 126, 4340-4340	2.2	
100	Microenvironmental Interactions up-Regulate CD20 Expression in CLL B Cells through the CXCR4/SDF-1 Axis: Implications for CD20-Targeting Antibodies and the Use of BCR-Inhibitors in Combination. <i>Blood</i> , 2015 , 126, 4124-4124	2.2	
99	Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 β for relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 123, 3390-7	2.2	487
98	Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. <i>Leukemia and Lymphoma</i> , 2014 , 55, 263-9	1.9	22
97	A new era of treatment for chronic lymphocytic leukaemia?. <i>Lancet Oncology, The</i> , 2014 , 15, 3-5	21.7	2
96	Somatic mutation as a mechanism of Wnt/ β catenin pathway activation in CLL. <i>Blood</i> , 2014 , 124, 1089-98	2.2	56
95	Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. <i>New England Journal of Medicine</i> , 2014 , 371, 213-23	59.2	1154
94	Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. <i>Nature</i> , 2014 , 511, 616-20	50.4	507

93	A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. <i>British Journal of Haematology</i> , 2014 , 167, 149-61	4.5	22
92	A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). <i>Blood</i> , 2014 , 123, 3398-405	2.2	206
91	Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2067-73	2.2	55
90	Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1390-8	4.7	14
89	Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- β as therapy for previously treated indolent non-Hodgkin lymphoma. <i>Blood</i> , 2014 , 123, 3406-13	2.2	173
88	Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 124, 42-8	2.2	50
87	Novel treatments for chronic lymphocytic leukemia and moving forward. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e317-25	7.1	17
86	The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF- κ B activation and induces apoptosis in chronic lymphocytic leukemia B cells. <i>Clinical Cancer Research</i> , 2014 , 20, 1576-89	12.9	91
85	Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 920-8	1.9	23
84	Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. <i>Cancer Cell</i> , 2014 , 26, 813-825	24.3	216
83	Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. <i>JAMA Dermatology</i> , 2014 , 150, 280-7	5.1	55
82	B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292. <i>ImmunoTargets and Therapy</i> , 2014 , 3, 29-38	9	6
81	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014 , 124, 3331-3331	2.2	19
80	Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 329-39	3.1	7
79	Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. <i>Current Hematologic Malignancy Reports</i> , 2013 , 8, 1-6	4.4	68
78	Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1823-5	1.9	21
77	Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. <i>Cell</i> , 2013 , 152, 714-26	56.2	1006
76	MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. <i>Blood</i> , 2013 , 121, 2051-8	2.2	298

75	Gastric mucosa-associated lymphoid tissue lymphoma resistant to <i>Helicobacter pylori</i> eradication: what's the best option?. <i>Leukemia and Lymphoma</i> , 2013 , 54, 899-900	1.9	
74	Genomic approaches to chronic lymphocytic leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 157-71	3.1	1
73	Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013 , 163, 123-6	4.5	56
72	A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Haematologica</i> , 2013 , 98, 964-70	6.6	10
71	Inherited susceptibility to chronic lymphocytic leukemia: evidence and prospects for the future. <i>Therapeutic Advances in Hematology</i> , 2013 , 4, 298-308	5.7	9
70	SF3B1 Mutation Alters The Selection Of 3' RNA Splice Sites In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013 , 122, 117-117	2.2	1
69	Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013 , 122, 1630-1630	2.2	25
68	Effect Of MYD88 Mutation In CLL On IRAK4 and BTK Inhibition In Vitro. <i>Blood</i> , 2013 , 122, 4132-4132	2.2	2
67	Increased Local Disorder of DNA Methylation Forms the Basis of High Intra-Leukemic Epigenetic Heterogeneity and Enhances CLL Evolution. <i>Blood</i> , 2013 , 122, 596-596	2.2	4
66	NF-B Pathway Mutations Modulate Cell Survival and Ibrutinib Response In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013 , 122, 670-670	2.2	5
65	SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study. <i>Blood</i> , 2013 , 122, 86-86	2.2	8
64	Inhibition Of Lyn and Syk By Treatment With Dasatinib, Fludarabine, and Rituximab Correlates With Apoptosis and Clinical Response In Patients With Relapsed CLL. <i>Blood</i> , 2013 , 122, 5300-5300	2.2	
63	Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. <i>Blood</i> , 2012 , 120, 3501-9	2.2	107
62	Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. <i>Clinical Cancer Research</i> , 2012 , 18, 3791-802	12.9	69
61	Targeting the B cell receptor pathway in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2362-70	1.9	68
60	Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. <i>Journal of Clinical Oncology</i> , 2012 , 30, 488-96	2.2	622
59	Risk Alleles Identified in Genome-Wide Association Studies Are Associated with Expression Quantitative Trait Loci in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012 , 120, 2875-2875	2.2	1
58	Functional Somatic and Germline Variants in the NF-B Pathway in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 560-560	2.2	3

57	Somatic Mutation As a Mechanism of Wnt/ β Catenin Pathway Activation in CLL. <i>Blood</i> , 2012 , 120, 559-559	2.2	
56	Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012 , 120, 1892-1892	2.2	
55	The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. <i>Blood</i> , 2012 , 120, 3865-3865	2.2	
54	Prior Treatment with Chemotherapy Is Associated with Poor Outcomes of High Risk Skin Cancers in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 3920-3920	2.2	
53	Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. <i>Blood</i> , 2012 , 120, 1980-1980	2.2	
52	Somatic and Germline Copy Neutral Loss of Heterozygosity Are Common in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 4567-4567	2.2	
51	The Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 5-5	2.2	
50	SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2011 , 365, 2497-506	59.2	875
49	Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. <i>Clinical Cancer Research</i> , 2011 , 17, 2977-86	12.9	103
48	The treatment of relapsed refractory chronic lymphocytic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2011 , 2011, 110-8	3.1	33
47	Insulin receptor activation in deletion 11q chronic lymphocytic leukemia. <i>Clinical Cancer Research</i> , 2011 , 17, 2605-7	12.9	5
46	Shifts in Intra-Clonal Dynamics Rather Than Novel Mutations Are the Main Engine Driving Tumor Evolution in Relapsed CLL. <i>Blood</i> , 2011 , 118, 284-284	2.2	0
45	Obatoclax in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL. <i>Blood</i> , 2011 , 118, 2865-2865	2.2	1
44	Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations. <i>Blood</i> , 2011 , 118, 288-288	2.2	3
43	Sensitivity to Wnt Pathway Inhibition in CLL Is Associated with Specific Gene Expression Signatures. <i>Blood</i> , 2011 , 118, 801-801	2.2	1
42	Novel Germline Genetic Variants Associated with Familial Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2011 , 118, 465-465	2.2	
41	Large-Scale CLL Genome Analysis Reveals Novel Cancer Genes, Including SF3B1. <i>Blood</i> , 2011 , 118, 463-463	2.2	
40	BH3 Profiling Demonstrates That Restoration of Apoptotic Priming Contributes to Increased Sensitivity to PI3K Inhibition in Stroma-Exposed Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011 , 118, 974-974	2.2	1

39	Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,. <i>Blood</i> , 2011 , 118, 3716-3716	2.2	
38	Rearrangement of 14q32 in the Absence of t(14;18) Is Associated with Short Time to First Treatment in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 1438-1438	2.2	
37	MicroRNA-155 As a Potential Plasma Biomarker for Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia,. <i>Blood</i> , 2011 , 118, 3669-3669	2.2	
36	LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 2728-2728	2.2	
35	Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. <i>British Journal of Haematology</i> , 2010 , 151, 336-45	4.5	11
34	Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1382-5	1.9	5
33	A Phase I Study of Escalated Dose Subcutaneous Alemtuzumab Given Weekly with Rituximab In Relapsed CLL/SLL.. <i>Blood</i> , 2010 , 116, 1381-1381	2.2	1
32	Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 α In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2010 , 116, 1777-1777	2.2	45
31	CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 α Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010 , 116, 55-55	2.2	38
30	Phenotypic Changes Associated with Acute Reductions In Leukemia Cell Counts In Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Lenalidomide as Initial Therapy. <i>Blood</i> , 2010 , 116, 59-59	2.2	1
29	High Resolution Genomic Analysis In CLL Demonstrates Genomic Stability In Untreated Patients and Novel Markers of Progression In Treated Patients. <i>Blood</i> , 2010 , 116, 2426-2426	2.2	
28	BH3 Profiling Demonstrates Decreased Mitochondrial Priming for Apoptosis In Primary CLL Cells Exposed to Stroma. <i>Blood</i> , 2010 , 116, 692-692	2.2	
27	Response to Dasatinib In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Correlates with p-Lyn and p-Syk. <i>Blood</i> , 2010 , 116, 2457-2457	2.2	
26	Amplification of 6p Associated with Familial CLL. <i>Blood</i> , 2010 , 116, 2432-2432	2.2	
25	Improved Outcome of CLL Patients with Leukemic Clones Expressing Mutated IGHV May Not Be Due to An Inability to Bind (auto)Antigen In Vivo. <i>Blood</i> , 2010 , 116, 2441-2441	2.2	
24	Reply to J. Mehta. <i>Journal of Clinical Oncology</i> , 2009 , 27, e139-e140	2.2	
23	A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. <i>British Journal of Haematology</i> , 2009 , 145, 741-8	4.5	69
22	Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. <i>British Journal of Haematology</i> , 2008 , 143, 361-8	4.5	23

21	Inherited predisposition to chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2008 , 1, 51-61	2.8	17
20	Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 1923-30	2.2	254
19	Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008 , 112, 972-972	2.2	4
18	Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 1057-65	4.7	52
17	Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. <i>Journal of Clinical Investigation</i> , 2007 , 117, 112-21	15.9	468
16	A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.. <i>Blood</i> , 2007 , 110, 1358-1358	2.2	2
15	A Phase II Study of Dasatinib in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL/SLL).. <i>Blood</i> , 2007 , 110, 3126-3126	2.2	8
14	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007 , 110, 4496-4496	2.2	2
13	Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma.. <i>Blood</i> , 2007 , 110, 2331-2331	2.2	
12	Non-Myeloablative Allogeneic Transplantation for Hodgkin's and Non-Hodgkin's Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. <i>Blood</i> , 2007 , 110, 3041-3041 ^{2,2}		
11	Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1056-64	4.7	99
10	Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia: Phase II Multicenter Study.. <i>Blood</i> , 2006 , 108, 4989-4989	2.2	
9	Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.. <i>Blood</i> , 2006 , 108, 3041-3041	2.2	
8	Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2208-14	2.2	102
7	Chronic lymphocytic leukemia: a niche for flavopiridol?. <i>Clinical Cancer Research</i> , 2005 , 11, 3971-3	12.9	12
6	Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen.. <i>Blood</i> , 2005 , 106, 2125-2125 ^{2,2}		0
5	The Molecular Basis for BCL-2 Oncogene Addiction in CLL.. <i>Blood</i> , 2005 , 106, 5008-5008	2.2	
4	Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2004 , 45, 315-20	1.9	15

3	Clinical mimics of lymphoma. <i>Oncologist</i> , 2004 , 9, 406-16	5-7	58
2	Hodgkin disease associated with T-cell non-Hodgkin lymphomas: case reports and review of the literature. <i>American Journal of Clinical Pathology</i> , 2004 , 121, 701-8	1-9	7
1	Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2437-8	2-2	10